BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

News & Events

BD to Present at Investor Healthcare Conferences

BD Announces Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock

BD Announces Commencement of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

BD 2017 Second Fiscal Quarter Financial Presentation

BD Announces Results for 2017 Second Fiscal Quarter

BD Acquires C.R. Bard Presentation

BD Announces Appointment of Tom Polen as President

BD to Acquire Bard for $24 Billion

BD Receives FDA 510(k) Clearance for New Flow Cytometer System with Leucocount Reagent Assay

BD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call

BD Completes Acquisition Of Caesarea Medical Electronics

BD To Present At Inaugural CECP CEO Investor Forum

BD Veritor™ System Meets FDA's New Performance Requirements for Rapid Influenza Antigen Detection Tests

BD Partnership Honored by U.S. Chamber of Commerce Foundation at the Health Means Business National Summit with Healthy10 Award

BD to Present at Investor Healthcare Conferences

BD Initiates New Industry Alliance To Combat Rising Opioid Crisis

New BD Institute For Medication Management Excellence Aims To Improve Patient Safety And Outcomes Through Collaboration

BD Board Declares Dividend

BD Announces Webcast of Annual Meeting of Shareholders

2016 Analyst Day Presentations

BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business

BD Unveils Next Generation Wireless Point-of-Care Diagnostic Device

BD Cited as Infusion Pump EMR Integration Leader in Klas Report

BD Receives FDA Clearance for New Syringe Designed for the Administration of Humulin® R U-500 Insulin

Annual Report
AdvaMed Life Changing Innovation
Sustainability Report 2014